← All trials
NCT05279313
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 24, 2022
- Primary completion
- May 10, 2024
- Completion date
- May 21, 2024
- First posted
- Mar 15, 2022
- Last posted
- Sep 2, 2022
- Enrollment
- 700
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- OtsukaLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.